EndoVas Medical Raises ￥10M in Additional Series Pre-A Funding

(VCBeat) Apr. 14, 2021 -- Recently, Shanghai EndoVas Medical Technology Co., Ltd. ("EndoVas Medical"), a company supported by Ruiling Capital, announced that it has obtained tens of millions in an additional Pre-Series A round of financing from Jiuzhixinfei. The new investment will be used to accelerate the development of medical devices for interventional therapy for veins, advance clinical trials and strengthen the R&D team. Prior to this, EndoVas Medical received an early-stage investment from Furong Capital and HiMed Angle Fund.

EndoVas Medical, founded in November 2018, is a high-tech enterprise focusing on the overall solution of venous diseases. Adhering to the tenet of "benefit from the public, reputation in the heart", the company provides patients with high-quality and high-performance peripheral medical products in veins through the international advanced innovative technology with independent intellectual property rights. EndoVas Medical is committed to creating "new domestic products" in terms of interventional therapies.

In just over two years, EndoVas Medical has developed a comprehensive treatment solution for lower extremity venous diseases such as varicose veins and pulmonary embolism and has extended the indications to the entire peripheral vascular field, which is of great significance as a milestone in the industry and has promoted the development of China's venous industry.

Wang Shengqiang, founder and CEO of EndoVas Medical, said, "The mission of EndoVas Medical is to respond to the call of the country and realize universal medical care. The core competitiveness is built by independent R&D. The senior team in the industry transforms the R&D achievements into products, develops venous disease treatment products that truly meet the clinical needs, and provides high-quality interventional medical devices for Chinese patients."

At present, the peripheral venous intervention market is dominated by imported products. The founders and team of EndoVas Medical have the capability of continuous breakthrough and innovation and iteration of products. The company is capable of breaking the import monopoly in the field of peripheral venous intervention and becoming the leading company in this field.

Founded in July 2018, Ruiling Capital is a professional FA institution that mainly provides equity investments and financial consulting services for medical companies in the Pre-Series A to Series C rounds. So far, the company has served dozens of enterprises and supported investments with a total amount of hundreds of millions of yuan.